Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 12/20 | 0.49 |
| ▸ | CTSB | P07858 | 8/20 | 0.49 |
| ▸ | CTSS | P25774 | 7/20 | 0.49 |
| ▸ | CTSK | P43235 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CTSV | O60911 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517733 | 0.87 | CTSL (0.51) | CTSLCTSBCTSSCTSKNPC1 | |
| SCHEMBL6447899 | 0.83 | CTSL (0.54) | CTSLCTSBCTSSCTSKNPC1 | |
| SCHEMBL5524114 | 0.79 | CTSL (0.56) | CTSLCTSBCTSSCTSKSMN1; SMN2 | |
| SCHEMBL5527001 | 0.78 | ESRRG (0.51) | CTSLCTSBCTSSCTSKNPC1 | |
| SCHEMBL5521783 | 0.77 | CTSL (0.48) | CTSLCTSBCTSSCTSKNPC1 | |
| SCHEMBL2863808 | 0.76 | GAA (0.61) | CTSLCTSBCTSSCTSKSMN1; SMN2 | |
| SCHEMBL5530345 | 0.76 | CTSL (0.62) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL5530348 | 0.76 | CTSL (0.62) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL5517758 | 0.75 | CTSK (0.61) | CTSLCTSBCTSSCTSKNPC1 | |
| SCHEMBL5526526 | 0.75 | ALDH1A1 (0.53) | CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| EP-1178958-B1 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030096796-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-05-22 | — | — | US | disclosed |
| US-6455502-B1 | Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096796-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CTSL 14/4885CTSB 11/4885CTSS 10/4885 |
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | CTRL, SERPINB1, CPN1 | CTSL 14/4885CTSB 11/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.